Lucid Diagnostics
Commercializes EsoGuard testing on esophageal cells collected with EsoCheck.
Something off on this page? Send us feedback.
Profile
Commercializes EsoGuard DNA testing using esophageal cells collected with EsoCheck. Revenue comes from patient test results, is concentrated in the United States, and is managed as one operating segment.
Commercializes one office-based esophageal cancer-prevention workflow for GERD patients at risk of Barrett's esophagus and esophageal adenocarcinoma. EsoGuard is the DNA test; EsoCheck is the swallowable cell-collection device used to gather lower-esophageal samples.
Revenue comes from patient EsoGuard test results and is concentrated in the United States. The business is managed as a single operating segment, with LucidDx Labs handling the testing workflow rather than a broad diagnostics menu.
Execution depends on reimbursement expansion, especially Medicare coverage, and on continued commercial access to laboratory-developed tests. The company also relies on outside capital while it scales test adoption.
Company facts
Categories
Key statistics
Year to date −11.0% · Average volume (30d) 1.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| May 15, 2026 | Maxim Group | Reiterate | Buy | $2 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.06 | −$0.06 | −5.9% | $1.4M | $1.5M | +3.3% | −1.98% |
| May 14, 2026Q1 FY26 | −$0.05 | −$0.07 | −40.0% | $1.4M | $1.3M | −9.0% | −2.83% |
| Mar 25, 2026Q4 FY25 | −$0.07 | −$0.10 | −42.9% | $1.4M | $1.5M | +10.4% | −3.36% |
| Nov 12, 2025Q3 FY25 | −$0.06 | −$0.10 | −66.7% | $1.4M | $1.2M | −12.7% | −3.60% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $828.0K | $1.2M | $1.2M | $1.5M | $1.3M | $1.5M | |
| Gross profit | −$723.0K | −$622.0K | −$486.0K | −$356.0K | −$591.0K | $29.0K | |
| Operating income | −$12.5M | −$11.4M | −$11.8M | −$14.0M | −$12.1M | −$12.8M | |
| Net income | −$26.9M | −$4.4M | −$10.4M | −$16.3M | −$13.9M | −$11.7M | |
| Diluted EPS | −$0.52 | −$0.08 | −$0.10 | −$0.12 | −$0.17 | −$0.08 | |
| Gross margin | -87.3% | -53.5% | -40.1% | -23.7% | -47.1% | 2.0% | |
| Operating margin | -1,508.1% | -978.8% | -971.0% | -931.6% | -964.5% | -868.5% |
Fiscal years (4-quarter sums)FY21 $500.0K · FY22 $377.0K · FY23 $2.4M · FY24 $4.3M · FY25 $4.7M
Balance sheet, Jun 30, 2026Cash & short-term investments $33.4M · Total debt $24.9M · Total assets $38.9M · Shareholders' equity $10.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 190.77M · Float 140.58M · 73.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| PAVmed Inc. | 38.82M | 27.50% | 13D | Feb 9, 2026 |
| BlackRock, Inc. | 4.64M | 2.43% | 13F | May 13, 2026 |
| Vanguard Capital Management LLC | 4.15M | 2.18% | 13F | May 15, 2026 |
| Masters Capital Management LLC | 4.00M | 2.10% | 13F | May 15, 2026 |
| Abrdn PLC | 3.64M | 1.91% | 13F | Apr 29, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 20, 2026 | Dennis Matheis | director | +245,000 | $1.00 |
Peers
- Castle Biosciences
Direct Barrett's esophagus molecular risk-stratification peer
- Abbott
Scaled cancer-screening owner after Exact Sciences acquisition
- Medtronic
Procedure and endoscopy alternative in esophageal workflows
- Guardant Health
Blood-based oncology screening and reimbursement competitor
- Natera
Large cfDNA testing platform competing for oncology diagnostics budgets
- Quest Diagnostics
National lab channel with oncology and advanced diagnostics scale
- Labcorp
Scaled specialty-testing lab competing for diagnostics access
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lucid Diagnostics | $1.00 | +0.36% | $189.1M | — | — | 34.7 | +26.7% |
| Castle Biosciences | $33.50 | +0.18% | $1.02B | — | — | 2.9 | +20.1% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Median | 26.7 | 18.5 | 3.2 | +13.0% |